On June 28, 2018, the Company announced that it had successfully completed the initial stage of this trial, which comprised the single dosing of healthy volunteers. The final stage of the trial comprises the twice daily dosing of healthy volunteers for 6 weeks

We mentioned in our recent letter to shareholders that we were waiting for licenses in order to initiate this trial. This approval has now been obtained and we will immediately initiate clinical testing. Validation of safe and efficacious therapeutics is key to our mission and we aim to progress our studies as rapidly as possible, adhering to best clinical practices”.

I feel a dip to 12-.14 is coming.

our group unloaded some 12's & 13's today for a nice flip

Zeevi took the credit when Nemas died

we are only responding to the continuous posted mistruths by certain members

our group is tired of waiting for lift off. so, we are unloading every single share of this company and we don't care at what price

Novel condom comprising cannabis derived compositions for enhancement of sexual pleasure and decrease of erectile dysfunction symptoms(10 pages)
https://www.freshpatents.com/-dt20171228ptan20170367875.php

But since this is a scam company

Dr. Oron Yacoby Zeevi, age 57, Chief Scientific Officer : Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry. In 2008, Dr. Yacoby Zeevi joined Neuroderm Ltd (Nasdaq: NDRM), a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders as the Vice President of Research and was promoted to the position of VP R&D. From October 2016 until her recent departure, she served as Chief Scientific Officer of Neuroderm, which was sold to Mitsubishi Tanabe Pharma for US $1.1 billion in July 2017. Dr. Yacoby Zeevi, is the inventor of over 50 issued patents and patents pending, Her expertise lies in industry-oriented innovation and scientific research, accelerating and orchestrating the evolution of new ideas through R&D PoC, IP, CMC, early efficacy and safety trials, regulatory affairs and market landscape mapping in fields of unmet medical needs, towards development of commercially viable pharmaceutical or agricultural products. Dr. Yacobi Zeevi earned her PHD in micro biology and immunology from the Ben Gurion University of Be’er Sheva, Israel and also holds a degree of Doctor in Veterinary Medicine from the Hebrew University of Jerusalem?

Those clowns are reading the board

The field in which we operate is increasingly crowded with unproven products. We believe that the companies that will succeed in such a market, will be the ones which have invested their resources in providing validated proof of efficacy and safety for their products. In the past, we have spoken of “market ready” products. This definition related to formulated products which were potentially marketable without the validation that I have eluded to above. We have made the decision that we do not want to compete in this undifferentiated market. Whilst in the short term, this will delay our commercial development, in the long term, this should be strongly value generating for our company and our shareholders.

Wait till it hits .15, then .12

100% profit for us

“OWCP is being investigated by the SEC”

“I know more about the patent process than anyone on the OWCP board. “

It doesn’t look like it! LOL

“First, the $5 million isn't guaranteed - you need to read the Equity Purchase Agreement - OWCP has to file a S-1 and the SEC has to deem it effective - that won't happen since there is a ongoing investigation. “


SEC declared $OWCP's S-1 effective...END of OWCP investigation nonsense

Repeated Misleading News

"Show me $OWCP owns 31 distinct patent applications"

"Show me $OWCP owns 31 granted patents"


Truth

"our intellectual property portfolio comprises nine patent families and includes 31 filings in selected domains at various stages from the Patent Cooperation Treaty (“PCT”) filings, National Phase filings and Continuations in Part (CIP)."

Truth

$OWCP owns 31 registered patent applications in various international patent organizations.

You gave 5 different incorrect calculations on the cost. I will help you with the correct calculation here.

First, here are your 5incorrect calculations.

“OWCP paid at a minimum of $11,875,000”

“ equity purchase agreement will cost OWCP/Shareholders over $11 million”

“Let's take a much closer look …So the is $100,000 + $575,000 + $375,000 = $1,050,000”

“Newbridge receives a unheard of finders fee of 2,500,00 x $0.20 = $500,000 Plus $375,000 Plus $100,000 .... For a grand total of $975,000”

“Here you go - Newbridge 2,500,000 shares plus $375,000 - that is $482,500 at todays price times the 2,500,000 - that equals $857,500.”

Here is the correct one. Hope this helps.

"Newbridge Securities Corporation (“Newbridge”), through LifeTech Capital, acted as exclusive placement agent for the transaction and we paid Newbridge a cash fee of $375,000 and issued to them warrants to purchase 2.5 million shares of our common stock at an exercise price of $0.20 per share."


I will explain it for you

Q: What is a 'Warrant'?
A: A warrant is a security that entitles the holder to buy the underlying stock of the issuing company at a fixed price called exercise price until the expiry date.

Newbridge is issued warrants to purchase 2.5 million shares of OWCP common stock at an exercise price of $0.20 per share. What this means is that if they exercise the warrants, then OWCP will receive $500,000. This will make the $375,000 cash fee a wash with OWCP still having $125,000 to cover the warrants solicitation fee equal to 4% of the gross proceeds that OWCP will receive upon cash exercise of the Warrants.

This means that if Newbridge exercises the warrants to purchase 2.5 million shares of OWCP common stock from OWCP at an exercise price of $0.20 per share, then OWCP would end up having paid Newbridge ONLY 2.5 million shares of common stock, AND ZERO CASH. In fact OWCP will end up with $105,000.

2.5 million shares X .20 = $500,000 (Money paid to OWCP upon exercise of warrants)

So now that it is understood that it is OWCP that is receiving the .20/share and it is Newbridge that is paying the .20/share upon exercising the Warrants, let's finish calculating how this works out.


+$500,000 Proceeds paid to OWCP by Newbridge
-$375,000 Cash fee paid to Newbridge by OWCP
——————————————————————————————————
+$125,000 Remaining proceeds that were paid to OWCP from the Warrants
——————————————————————————————————
-$20,000 4% fee of the gross proceeds that OWCP will receive upon cash exercise of the Warrants
——————————————————————————————————
+$105,000 Remaining proceeds paid to OWCP by Newbridge (after Newbridge exercises Warrants)


So if Newbridge exercises the Warrants then their services would have cost OWCP
2.5 million shares of common stock; and actually OWCP will come out with $105,000 cash in addition to their services.

The paragraph you keep posting says "up to 47,500,000 shares of our common stock"

as in UP TO...


12,500,000 of the 47,500,000 shares of common stock will be from the Warrants if Discover Growth Fund exercises the Warrants.

If they do exercise the Warrants then Discover Growth Fund will pay OWCP an additional $2,750,000

12,500,000 X .22 = $2,750,000


OWCP will then pay Newbridge a commission on the proceeds from exercised Warrants of 4% which is $110,000.

So OWCP will receive an additional $2.64 Million if Discover Growth Fund exercises the Warrants.

Hope are you starting to kind of understand how Warrants work.
That's not a bad deal at all. “

What is apparent is you made a stupid trade